Knowledge is Power: ovarian cancer

•

8 j'aime•1,895 vues

The document discusses a clinical trial called GOG 218 that evaluated the use of the drug bevacizumab for the primary treatment of advanced epithelial ovarian cancer. The trial found that patients who received bevacizumab plus chemotherapy had a 3 month improvement in progression-free survival compared to those who received chemotherapy alone. Bevacizumab is the first molecular targeted therapy and anti-angiogenic agent to demonstrate a benefit in upfront treatment of ovarian cancer. While survival was not yet improved, the trial provides support for further research evaluating bevacizumab and other targeted agents to improve outcomes for ovarian cancer patients.

Formation Santé & Médecine Business

Epithelial Ovarian Cancer: Bevacizumab and GOG 218 Mildred R. Chernofsky, MD Associate Clinical Professor Department of Obstetrics and Gynecology George Washington University Sibley Center for Gynecologic Oncology and Advanced Pelvic Surgery 29 September 2010

Ovarian Cancer ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],American Cancer Society, Cancer Facts and Figures 2010

Tumor Staging ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Tumor Debulking Optimal tumor debulking confers an 11 month median survival advantage over the median survival of suboptimal patients

Following Surgery  Chemotherapy for Advanced Ovarian Cancer ,[object Object],[object Object]

Trends in Five-year Relative Survival (%)# Rates, US, 1975-2005 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],# 5-year relative survival rates based on follow up of patients through 2006. Source: Horner et al, SEER Cancer Statistics Review, 1975-2006, NCI, Bethesda, MD, seer.cancer.gov/csr/1975_2006/,2009. Site 1975-1977 1984-1986 1999-2005 * The difference in rates between 1975-1977 and 1999-2005 is statistically significant, (p < 0.05%)

Can we make survival better in ovarian cancer ? Is the answer biologics?

Angiogenesis ,[object Object],[object Object],[object Object]

Bevacizumab (Avastin © ) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Avastin© is manufactured by Genentech/Roche

Frumovitz F and Sood AK. Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol 2007; 104:768-778. Bevacizumab in Recurrent Ovarian Cancer

Definitions ,[object Object],[object Object],cancer.gov

GOG 218: Phase III Trial of Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: A Gynecologic Oncology Group (GOG) Study Slide courtesy of the Gynecologic Oncology Group (GOG) and provided by Dr. Robert A. Burger, ASCO 2010

Phase III Trial of Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: A Gynecologic Oncology Group (GOG) Study ,[object Object],[object Object],[object Object],[object Object],[object Object],Burger et al, ASCO 2010

Future research ,[object Object],[object Object]

Conclusions ,[object Object],[object Object],[object Object]

Questions / Acknowledgements ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Contenu connexe

Tendances

Screening for ovarian cancer may 15Basalama Ali

Dr. Ginger Gardner on Recurrent Ovarian Cancer (SHARE Program)bkling

Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Endo...European School of Oncology

updated overview in management of ovarian cancerSajan Thapa

Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD Ovarian Cancer Research Fund Alliance

Metastatic ovarian cancerHarsh Parmar

The Role of Surgery in the Management of Ovarian CancerSibley Memorial Hospital

05052008OvarianTelehealthFlavio Guzmán

Is there a role for ovarian cancer screeningMing Cheng

Ovarian cancer pptVidya Dhonde

Ovarian & endometrial cancerIsha Jaiswal

Metastatic pancreatic cancer final pptH Reddy

Current pancreatic cancer research 10 May 16Derek Louden

Ovarian Cancer: Treatment Options after DiagnosisSibley Memorial Hospital

Role of chemotherapy in ovarian cancerAnita Singh

Lymphadenectomy for gynecological cancersDr./ Ihab Samy

MCO 2011 - Slide 14 - C. Sessa - Cervical and endometrial cancers (part I)European School of Oncology

Ovarian Cancer: Symptoms, Diagnosis and BRCA Testing for High Risk IndividualsSibley Memorial Hospital

2014 Sigma Xi PowerPoint PresentationEmily05

Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...European School of Oncology

Tendances (20)

Screening for ovarian cancer may 15

Dr. Ginger Gardner on Recurrent Ovarian Cancer (SHARE Program)

Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Endo...

updated overview in management of ovarian cancer

Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD

Metastatic ovarian cancer

The Role of Surgery in the Management of Ovarian Cancer

05052008OvarianTelehealth

Is there a role for ovarian cancer screening

Ovarian cancer ppt

Ovarian & endometrial cancer

Metastatic pancreatic cancer final ppt

Current pancreatic cancer research 10 May 16

Ovarian Cancer: Treatment Options after Diagnosis

Role of chemotherapy in ovarian cancer

Lymphadenectomy for gynecological cancers

MCO 2011 - Slide 14 - C. Sessa - Cervical and endometrial cancers (part I)

Ovarian Cancer: Symptoms, Diagnosis and BRCA Testing for High Risk Individuals

2014 Sigma Xi PowerPoint Presentation

Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...

En vedette

HPV Vaccinejilldc

Avoiding RecurrenceGeorge S. Ferzli

Targeted therapy in ovarian cancerBasalama Ali

Endometrial Carcinoma.Adjuvant Treatmentbalaganoff

Recent updates in hpv vaccinesDr. Sunaina Wadhwa

J.B. Vermorken - Ovarian cancer - State of the artEuropean School of Oncology

Targetted agents in head and neck cancersSanudev Vadakke Puthiyottil

Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)bkling

Ovarian cancer Tariq Mohammed

Prophylactic Cytoreduction and HIPECMichail Papoulas

Basics of Immunohistochemistry Jacob Lyons

Benign ovarian tumoursSravanthi Nuthalapati

Endometrial Cancer; Evidence Based ApproachFaculty of Medicine - Benha University

principle of Immunohistochemistry and its use in diagnosticsEkta Jajodia

Immunohistochemistry is an important complimentary tool for diagnosis of cancer"Lawrence Richards

Ovarian cancer by dr.saleh bakarSaleh Bakar

Cervical CancerGregorio Urruela Vizcaíno

Fluorescent in-situ Hybridization (FISH)BioGenex

Ovarian CancerGregorio Urruela Vizcaíno

Cervical cancer pptManali Solanki

En vedette (20)

HPV Vaccine

Avoiding Recurrence

Targeted therapy in ovarian cancer

Endometrial Carcinoma.Adjuvant Treatment

Recent updates in hpv vaccines

J.B. Vermorken - Ovarian cancer - State of the art

Targetted agents in head and neck cancers

Dr. Paul Sabbatini: Recurrent Ovarian Cancer: Now What? (SHARE Program)

Ovarian cancer

Prophylactic Cytoreduction and HIPEC

Basics of Immunohistochemistry

Benign ovarian tumours

Endometrial Cancer; Evidence Based Approach

principle of Immunohistochemistry and its use in diagnostics

Immunohistochemistry is an important complimentary tool for diagnosis of cancer"

Ovarian cancer by dr.saleh bakar

Cervical Cancer

Fluorescent in-situ Hybridization (FISH)

Ovarian Cancer

Cervical cancer ppt

Similaire à Knowledge is Power: ovarian cancer

Cervical cancer - Role of screening and management of advanced stage cervical...Alok Gupta

O. Glehen - HIPEC Colorectal and GastricGlehen

Pancreatic Cancer Are We Moving Forward Yetfondas vakalis

How to have quality of life in Advanced ovarian malignancyRajesh Gajbhiye

RESEARCH & TREATMENT NEWS: Highlights from the 2014 GI Cancer SymposiumFight Colorectal Cancer

Gi Cancer Symposium 2012 Report PresentationFight Colorectal Cancer

BALKAN MCO 2011 - J. Vermorken - First line treatment of ovarian cancer: surg...European School of Oncology

Hepatocellular & Pancreatic CarcinomasRHMBONCO

Original StudyType of Breast Cancer Diagnosis, Screening,a.docxvannagoforth

What 2015 Holds for Colorectal Cancer #CRCWebinarFight Colorectal Cancer

Role of Oral Gefitinib In Recurrent Carcinoma Cervix in Relation to EGFR StatusPremier Publishers

Who Benefits From Apbi March2009Spectrum Health

Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...iosrjce

34320294 jak inhibitors more than just glucocorticoids (1)EVELIN LÁZARO

Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on ...alessandrolealmd

Grazi breast cancer finalGian Luca Grazi

gopalan031607Flavio Guzmán

Vital Signs Edition #1ScottJordan

A retrospective study on ovarian cancer with a median follow-up of 36 months ...AI Publications

MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)European School of Oncology

Similaire à Knowledge is Power: ovarian cancer (20)

Cervical cancer - Role of screening and management of advanced stage cervical...

O. Glehen - HIPEC Colorectal and Gastric

Pancreatic Cancer Are We Moving Forward Yet

How to have quality of life in Advanced ovarian malignancy

RESEARCH & TREATMENT NEWS: Highlights from the 2014 GI Cancer Symposium

Gi Cancer Symposium 2012 Report Presentation

BALKAN MCO 2011 - J. Vermorken - First line treatment of ovarian cancer: surg...

Hepatocellular & Pancreatic Carcinomas

Original StudyType of Breast Cancer Diagnosis, Screening,a.docx

What 2015 Holds for Colorectal Cancer #CRCWebinar

Role of Oral Gefitinib In Recurrent Carcinoma Cervix in Relation to EGFR Status

Who Benefits From Apbi March2009

Gemcitabine and Cisplatin In Metastatic Carcinoma Gallbladder. A Single Insti...

34320294 jak inhibitors more than just glucocorticoids (1)

Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on ...

Grazi breast cancer final

gopalan031607

Vital Signs Edition #1

A retrospective study on ovarian cancer with a median follow-up of 36 months ...

MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)

Plus de Sibley Memorial Hospital

Medical Staff Annual Education 2011 Sibley Memorial Hospital

Sibley Memorial Hospital Annual Education 2011Sibley Memorial Hospital

Orientation 2011-2012Sibley Memorial Hospital

Annual education 2011Sibley Memorial Hospital

$H:\2010 web updates\maternity tour3$ $H:\2010 web updates\maternity tour3$

H:\2010 web updates\maternity tour3Sibley Memorial Hospital

Sibley Memorial Hospital Maternity TourSibley Memorial Hospital

Physical Therapy: A Component of the Cancer Care PlanSibley Memorial Hospital

Genetics of Breast CancerSibley Memorial Hospital

Plus de Sibley Memorial Hospital (9)

Medical Staff Annual Education 2011

Sibley Memorial Hospital Annual Education 2011

Orientation 2011-2012

Annual education 2011

$H:\2010 web updates\maternity tour3$ $H:\2010 web updates\maternity tour3$

H:\2010 web updates\maternity tour3

Sibley Memorial Hospital Maternity Tour

Physical Therapy: A Component of the Cancer Care Plan

Genetics of Breast Cancer

Dernier

How to do quick user assign in kanban in Odoo 17 ERPCeline George

USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...Postal Advocate Inc.

Proudly South Africa powerpoint Thorisha.pptxthorishapillay1

ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxiammrhaywood

4.16.24 21st Century Movements for Black Lives.pptxmary850239

call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️9953056974 Low Rate Call Girls In Saket, Delhi NCR

Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)lakshayb543

AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdfphamnguyenenglishnb

AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptxiammrhaywood

LEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptxConquiztadors- the Quiz Society of Sri Venkateswara College

YOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptxConquiztadors- the Quiz Society of Sri Venkateswara College

Karra SKD Conference Presentation Revised.pptxAshokKarra1

Transaction Management in Database Management SystemChristalin Nelson

Global Lehigh Strategic Initiatives (without descriptions)cama23

ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...JhezDiaz1

Influencing policy (training slides from Fast Track Impact)Mark Reed

Keynote by Prof. Wurzer at Nordex about IP-designMIPLM

Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfJemuel Francisco

4.18.24 Movement Legacies, Reflection, and Review.pptxmary850239

Raw materials used in Herbal Cosmetics.pptxAshokrao Mane college of Pharmacy Peth-Vadgaon

Dernier (20)

How to do quick user assign in kanban in Odoo 17 ERP

USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...

Proudly South Africa powerpoint Thorisha.pptx

ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx

4.16.24 21st Century Movements for Black Lives.pptx

call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️

Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)

AMERICAN LANGUAGE HUB_Level2_Student'sBook_Answerkey.pdf

AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptx

LEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptx

YOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptx

Karra SKD Conference Presentation Revised.pptx

Transaction Management in Database Management System

Global Lehigh Strategic Initiatives (without descriptions)

ENGLISH 7_Q4_LESSON 2_ Employing a Variety of Strategies for Effective Interp...

Influencing policy (training slides from Fast Track Impact)

Keynote by Prof. Wurzer at Nordex about IP-design

Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf

4.18.24 Movement Legacies, Reflection, and Review.pptx

Raw materials used in Herbal Cosmetics.pptx

Knowledge is Power: ovarian cancer

1. Epithelial Ovarian Cancer: Bevacizumab and GOG 218 Mildred R. Chernofsky, MD Associate Clinical Professor Department of Obstetrics and Gynecology George Washington University Sibley Center for Gynecologic Oncology and Advanced Pelvic Surgery 29 September 2010

5. Tumor Debulking Optimal tumor debulking confers an 11 month median survival advantage over the median survival of suboptimal patients

9. Can we make survival better in ovarian cancer ? Is the answer biologics?

10.

11.

12. Eskens FA and Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review. Eur J Cancer 2006; 42: 3127-3139. Blood vessel formation

13.

14.

15. Frumovitz F and Sood AK. Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol 2007; 104:768-778. Bevacizumab in Recurrent Ovarian Cancer

16.

17.

18. GOG 218: Phase III Trial of Bevacizumab in the Primary Treatment of Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer: A Gynecologic Oncology Group (GOG) Study Slide courtesy of the Gynecologic Oncology Group (GOG) and provided by Dr. Robert A. Burger, ASCO 2010

19.

20.

21.

22.

23.

24.

Notes de l'éditeur

The survival rates for all cancers combined and for certain site-specific cancers have improved significantly since the 1970s, due, in part, to both earlier detection and advances in treatment. Survival rates markedly increased for cancers of the prostate, breast, colon, rectum, and for leukemia. With new treatment techniques and increased utilization of screening, there is hope for even greater improvements in the not-too-distant future.

Knowledge is Power: ovarian cancer

Recommandé

Recommandé

Contenu connexe

Tendances

Tendances (20)

En vedette

En vedette (20)

Similaire à Knowledge is Power: ovarian cancer

Similaire à Knowledge is Power: ovarian cancer (20)

Plus de Sibley Memorial Hospital

Plus de Sibley Memorial Hospital (9)

Dernier

Dernier (20)

Knowledge is Power: ovarian cancer

Notes de l'éditeur